Novavax, Inc.

Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Our vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical to disease pathogenesis.

 

Bank Name Novavax, Inc.
Stock Exchange NASDAQ
Symbol NVAX
Sector Healthcare
Industry Biotechnology: Biological Products
Country United States
World Region Amarica
Chairman
CEO Mr. Stanley Charles Erck
Employees 1987
Website www.novavax.com
Registered Year 1987

 

UpdateContent
UpdateContent
UpdateContent